Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.
2.

A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.

Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ.

J Womens Health (Larchmt). 2015 Apr;24(4):281-90. doi: 10.1089/jwh.2014.4900.

PMID:
25860107
3.

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.

J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu.

PMID:
20797382
4.

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Clayton AH, Kornstein SG, Dunlop BW, Focht K, Musgnung J, Ramey T, Bao W, Ninan PT.

J Clin Psychiatry. 2013 Oct;74(10):1010-7. doi: 10.4088/JCP.12m08065.

PMID:
24229754
5.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.

Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.

PMID:
24096053
6.

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.

Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.

Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.

PMID:
23881185
7.
8.
9.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
10.

Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.

Iwata N, Tourian KA, Hwang E, Mele L, Vialet C.

J Psychiatr Pract. 2013 Jan;19(1):5-14. doi: 10.1097/01.pra.0000426323.59698.64.

PMID:
23334675
11.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.

Int Clin Psychopharmacol. 2007 Nov;22(6):338-47.

PMID:
17917552
12.
13.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
14.

Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.

Endicott J, Lam RW, Hsu MA, Fayyad R, Boucher M, Guico-Pabia CJ.

J Affect Disord. 2014 Sep;166:307-14. doi: 10.1016/j.jad.2014.05.011. Epub 2014 May 21.

PMID:
25012446
15.

The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.

Kornstein SG, Guico-Pabia CJ, Fayyad RS.

Hum Psychopharmacol. 2014 Sep;29(5):492-501. doi: 10.1002/hup.2427. Epub 2014 Aug 11.

PMID:
25196042
16.

Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.

Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ.

J Clin Psychopharmacol. 2011 Oct;31(5):569-76. doi: 10.1097/JCP.0b013e31822c0a68.

PMID:
21869698
17.

Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.

Soares CN, Fayyad RS, Guico-Pabia CJ.

J Clin Psychopharmacol. 2014 Feb;34(1):57-65. doi: 10.1097/JCP.0000000000000049.

PMID:
24346751
18.

Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.

Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ.

J Clin Psychopharmacol. 2010 Jun;30(3):294-9. doi: 10.1097/JCP.0b013e3181dcb594.

PMID:
20473066
20.

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.

Soares CN, Endicott J, Boucher M, Fayyad RS, Guico-Pabia CJ.

CNS Spectr. 2014 Dec;19(6):519-27. doi: 10.1017/S1092852914000066. Epub 2014 Feb 26.

PMID:
24571916

Supplemental Content

Support Center